JAK3/TEC and TYK2/JAK1 inhibitors demonstrate significant improvement in scalp alopecia areata biomarkers

We present the biopsy sub-study results from the first randomized, placebo-controlled clinical trial in patients with alopecia areata (AA) with ≥50% scalp hair loss and ≤7 years since the last AA episode. In this sub-study, we evaluated the molecular responses to PF-06651600, an oral inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family, and PF-06700841, an oral TYK2/JAK1 inhibitor, versus placebo in nonlesional and lesional scalp biopsies of biopsy samples from patients with AA. This is a novel design, phase 2a, multicenter study that evaluates the efficacy, safety, and tolerability of PF-06651600 and PF-06700841 versus placebo in patients with AA. The biopsy sub-study took place during the randomized, double-blind initial 24 weeks of the trial. 46 patients were included in the biopsy sub-study as follows: PF-06651600 (n=18), PF-06700841 (n=16), and placebo (n=12).